Showing results (131-140 of 790) with videos related to

Sort By:
Pageof 79
Plos One|October 28, 2015
Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple CancersVasudha Sehgal, Elena G Seviour, Tyler J Moss, et al.
Cell Death Discovery|August 4, 2023
Single-cell trajectory analysis reveals a CD9 positive state to contribute to exit from stem cell-like and embryonic diapause states and transit to drug-resistant statesXi Li, Alfonso Poire, Kang Jin Jeong, et al.
BMC Genomics|July 1, 2016
Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer typesTenghui Chen, Zixing Wang, Wanding Zhou, et al.
Cancer Research|May 20, 2004
Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell lineShankar Sellappan, Rebecca Grijalva, Xiaoyan Zhou, et al.
Cancer Research|November 3, 2017
Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome AtlasJun Li, Rehan Akbani, Wei Zhao, et al.
Molecular Endocrinology (Baltimore, Md.)|January 30, 2003
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancerXiaojiang Cui, Ping Zhang, Wanleng Deng, et al.
Bioinformatics (Oxford, England)|May 24, 2017
Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case studyNicolas Städler, Frank Dondelinger, Steven M Hill, et al.
American Journal of Cancer Research|April 14, 2016
Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasmChao Wang, Xiaoyong Zhu, Weiwei Feng, et al.
Current Biology : CB|January 22, 2013
Mask is required for the activity of the Hippo pathway effector Yki/YAPLeticia Sansores-Garcia, Mardelle Atkins, Ivan M Moya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2013
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinationsEvita M Lindholm, Marit Krohn, Sergio Iadevaia, et al.
Pageof 79